On September 22, 2026, Biocon Biologics Limited (“Biocon”) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products ...

Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon Biologics to consolidate its biosimilars and generics drug businesses.

On September 24, 2026, the USPTO Director issued a decision explaining the denial of institution of PGR2026-00039, filed by Biocon against ...

Biocon stock offers investors exposure to a diversified biopharmaceutical business that generated 4,336.0 crore rupees of ...

Biocon Electric has filed its DRHP with SEBI for a proposed IPO of up to 59 lakh shares, comprising a fresh issue and an ...

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

Peter Bains is vacating his seat on the Biocon board to take on the role of chief executive officer of Biocon Group as the Indian drugmaker looks to expand its place in emerging markets. (Biocon) ...

Biocon’s pertuzumab is the first biosimilar to secure EMA CHMP approval recommendation under a new tailored clinical approach.

Biocon Electric Ltd IPO 1970 - Get Biocon Electric Ltd open and close date, listing date, price band, IPO lot size, allotment, subscription status, review, key insights, and much more only at Business ...

Promoter Biocon Limited sold 80 lakh shares in Syngene International for an average price of Rs 857.68. via a bulk deal on ...